EC authorizes new use for ofatumumab in CLLDecember 14, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
EC grants venetoclax conditional approval for CLLDecember 9, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA grants priority review to sBLA for pembrolizumabDecember 2, 2016Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
FDA grants full approval for ponatinibNovember 30, 2016Leukemia, Myelodysplasia, TransplantationPharmacyALLCML
NICE recommends taking ibrutinib off CDFNovember 30, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Tazemetostat receives fast track designation for DLBCLNovember 29, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
EC approves nivolumab for relapsed/refractory cHLNovember 23, 2016Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
Company withdraws application for eryaspase in ALLNovember 16, 2016Leukemia, Myelodysplasia, TransplantationPharmacyALL